In light of the ACLU versus Myriad Genetics case, David Ewing Duncan at Tech Review asks the age-old question: "Should human DNA be owned?" In the US, Duncan says that an individual's BRCA1 gene cannot be patented, but that Myriad could patent a mutated gene sequence associated with breast cancer. Then, patients' genes could be compared to the patented sequence -- that is what the ACLU and other plaintiffs say is a mistake. Duncan says the complaint is beside the point.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.